Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma

Gene Therapy

Volumn 15, Issue 18, 2008, Pages 1257-1270

  Errington, F ^a   White, C L ^b   Twigger, K R ^b   Rose, A ^a   Scott, K ^a   Steele, L ^a   Ilett, L J ^a   Prestwich, R ^a   Pandha, H S ^c   Coffey, M ^d   Selby, P ^a   Vile, R ^e   Harrington, K J ^b,f   Melcher, A A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

^d ONCOLYTICS BIOTECH INC   (Canada)

^e MAYO CLINIC   (United States)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; CASPASE; CHEMOKINE; CYTOKINE; DACARBAZINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE P38; ONCOLYTIC VIRUS; RAL PROTEIN; RANTES; RAS PROTEIN; SYNAPTOPHYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL ACTIVATION; CELL KILLING; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; DRUG POTENCY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOGENICITY; INTERMETHOD COMPARISON; MELANOMA; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; REOVIRUS; VIRAL GENE THERAPY; VIRUS REPLICATION; XENOGRAFT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CHROMONES; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; HUMANS; IMIDAZOLES; MELANOMA; MORPHOLINES; ONCOLYTIC VIROTHERAPY; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RAS PROTEINS; REOVIRIDAE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ORTHOREOVIRUS;

EID: 51049090205     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2008.58     Document Type: Article

References (57)

1. Selb B, Weber B. A study of human reovirus IgG and IgA antibodies by ELISA and western blot. J Virol Methods 1994; 47: 15-25.
2. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334.
3. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW. The molecular basis of viral oncolysis: Usurpation of the Ras signaling pathway by reovirus. EMBO J 1998; 17: 3351-3362.
4. Strong JE, Lee PW. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol 1996; 70: 612-616.
5. Marcato P, Shmulevitz M, Lee PW. Connecting reovirus oncolysis and Ras signaling. Cell Cycle 2005; 4: 556-559.
6. Norman KL, Hirasawa K, Yang A, Shields MA, Lee PWK Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 2004; 101: 11099-11104.
7. Smakman N, van den Wollenberg DJ, Borel Rinkes IHM, Hoeben RC, Kranenburg O. Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovhms T3D. J Virol 2005; 79: 14981-14985.
8. Alain T, Kim TSY, Lun X, Liaciru A, Schiff LA, Senger DL et al. Proteolytic disassembly is a critical determinant for reovirus; oncolysis. Mol Ther 2007; 15: 1512-1521.
9. Marcato P, Shmulevitz M, Pan D, Stoltz D, Lee PWK Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol Ther 2007; 15 1522-1530.
10. Hirasawa K, Nishikawa SG, Norman KL, Alain T, Kossakowska A, Lee PWK Oncolytic reovirus against ovarian and colon cancer. Cancer Res 2002; 62: 1696-1701.
11. Norman KL, Coffey MC, Hirasawa K, Demetrick DJ, Nishikawa SG, DiFrancesco, LM et al. Reovirus oncolysis of human breast cancer. Hum Gene Therapy 2002; 13: 641-652.
12. Wilcox ME, Yang W, Senger D, Rewcastle NS, Morris DG, Brasher PMA et al. Reovirus as an oncolytic agent against experimental human malignant gliomas. J Natl Cancer Inst 2001; 93: 903-912.
13. Alain T, Hirasawa K, Pon KJ, Nishikawa SG, Urbanski SJ, Auer Y et al Reovirus therapy of lymphoid malignancies. Blood 2002; 100 4146-4153.
14. Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003; 22: 3087-3091.
15. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA et al In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006; 66: 9483-9491.
16. Garbe C, Eigentler TK. Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 2007; 17: 117-127.
17. Benencia F, Courreges MC, Conejo-García JR, Mohamed-Hadley A. Zhang L, Buckanovich RJ et al. HSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer. Mol Ther 2005; 12: 789-802.
18. Kedl RM, Rees WA, Hildeman DA, Schaefer B, Mitchell T, Kappler J et al. T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med 2000; 192: 1105-1113.
19. Diaz RM, Galivo F, Kottke T, Wongthida, P. Qiao J, Thompson J et al Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 2007; 67: 2840-2848.
20. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immunother 2005; 54: 587-598.
21. Schulz O, Diebold SS, Chen M, Näslund TI, Nolte MA, Alexopoulou L et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433: 887-892.
22. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon C et al. Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 2003; 63: 348-353.
23. Qiao J, Wang H, Kottke T, White C, Twigger K, Diaz RM et al. Cyclophosphamide facilitates antitumor efficacy against sub-cutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 2008; 14: 259-269.
24. Bennett DC, Cooper PJ, Hart IR. A line of non-tumorigenic mouse melanocytes, syngeneic with the B16 melanoma and requiring a tumour promoter for growth. Int J Cancer 1987; 39: 414-418.
25. Tyler KL, Squier MK, Rodgers SE, Schneider BE, Oberhaus SM, Grdina TA et al. Differences in the capacity of reovirus, strains to induce apoptosis are determined by the viral attachment protein sigma 1. J Virol 1995; 69: 6972-6979.
26. Connolly JL, Dermody TS. Virion disassembly is required for apoptosis induced by reovirus. J Virol 2002; 76: 1632-1641.
27. Clarke P, Tyler KL. Reovirus-induced apoptosis: A minireview. Apoptosis 2003; 8: 141-150.
28. Lee PW, Hayes EC, Joklik WK. Characterization of anti-reovirus immunoglobulins secreted by cloned hybridoma cell lines. Virology 1981; 108: 134-146.
29. Ikeda Y, Nishimura G, Yanorlia S, Kubota A, Furukawa M, Tsukuda M. Reovirus oncolysis in human head and neck squamous carcinoma cells. Auris Nasus Larynx 2004; 31: 407-412.
30. Melcher A, Gough M, Todryk S, Vile R. Apoptosis or necrosis for tumor inummotherapy: What's in a name? J Mol Med 1999; 77: 824-833.
31. Crittenden MR, Thanarajasingain U, Vile RG, Gough MJ. Intraturnoral immunotherapy: Using the tumour against itself. Immunology 2005; 114: 11-22.
32. Sinkovics JG. Viral oncolysates as human tumor vaccines. Int Rev Immunol 1991; 7: 259-287.
33. Mocellin S, Wang E, Marincola FM. Cytokines and immune response in the tumor microenvironment. J Immunother 2001; 24: 392-407.
34. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G et al. Increased levels of interleukin-10 in serum from patients with. hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 2004; 10: 7260-7269.
35. Shurin MR, Shurin GV, Lokshin A, Yurkovetsky ZR, Gutkin DW, Chatta G et al. Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: Friends or enemies? Cancer Metastasis Rev 2006; 25: 333-356.
36. Schuler G, Schuler-Thurner B, Steinman RM. The use of dendritic cells in cancer immunotherapy. Curr Opin Immunol 2003; 15: 138-147.
37. Robbins PF, Kawakami Y. Human tumor antigens recognized by T cells. Curr Opin Immunol 1996; 8: 628-636.
38. Elder D. Tumor progression, early diagnosis and prognosis of melanoma. Acta Oncol 1999; 38: 535-547.
39. Riker AL, Radfar S, Liu S, Wang Y, Khong HT et al. Immunotherapy of melanoma: A critical review of current concepts and future strategies. Expert Opin Biol Ther 2007; 7: 345-358.
40. Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: A new beginning? Crit Rev Oncol Hematol 2007; 62: 16-22.
41. Arpaia N, Cassano N, Vena GA. Regressing cutaneous malignant melanoma. and vitiligo-like depigmentation. Int J Dermatol 2006; 45: 952-956.
42. Daniels GA, Sanchez-Perez L, Diaz RM, Kottke T, Thompson J, Lai M et al. A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 2004; 22: 1125-1132.
43. Sanchez-Perez L, Kottke T, Daniels GA, Diaz RM, Thompson J, Pulido J et al. Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol 2006; 177: 4168-4177.
44. Shmulevitz M, Marcato P, Lee PW. Unshackling the links between reovirus oncolysis, Ras signaling, translational control and cancer. Oncogene 2005; 24: 7720-7728.
45. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005; 24: 165-183.
46. Matzinger P. An innate sense of danger. Semin Immunol 1998; 10 399-415.
47. Zeng J, Fournier P, Schirrmacher V. Induction of interferon-alpha and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by hemagglutinin-neuraminidase but not F protein of Newcastle disease virus. Virology 2002; 297: 19-30.
48. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001; 413: 732-738.
49. Williams ME, Cox DC, Stevenson JR. Rejection of reovirus-treated L1210 leukemia cells by mice. Cancer Immunol Immunother 1986; 23: 87-92.
50. Steele TA, Cox DC. Reovirus type 3 chemoinummotherapy of murine lymphoma is abrogated by cyclosporine. Cancer Mother 1995; 10: 307-315.
51. Moser B, Wolf M, Walz A, Loetscher P. Chemokines: Multiple levels of leukocyte migration control, Trends Immunol 2004; 25: 75-84.
52. Detournay O, Mazouz; N, Goldman M, Toungouz M. IL-6 produced by type I IFN DC controls IFN-gamma production by regulating the suppressive effect of CD4+ CD25+ regulatory T cells. Hum Immunol 2005; 66 460-468.
53. Taub DD, Ortaldo JR, Turcovski-Corrales SM, Key ML, Longo DL, Murphy WJ et al. Beta chemokines costimulate lymphocyte cytolysis, proliferation, and lymphokine production. J Leukoc Biol 1996; 59: 81-89.
54. Wegiel B, Bjartell A, Culig Z, Persson JL. Interleukin-6 activates PI3K/ Akt pathway and regulates cyclin A1 to promote prostate cancer cell survival. Int J Cancer 2008; 122: 1521-1529.
55. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y et al. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res 2007; 67: 6854-6862.
56. Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M et al. Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Therapy 2006; 13: 138-149.
57. Mirski SE, Evans CD, Almquist KC, Slovak ML, Cole SPC. Altered topoisomerase II alpha in a drug-resistant small cell lung cancer cell line selected in VP-16. Cancer Res 1993; 53: 4866-4873.